RK-33
Based on 5 publication(s) in Google Scholar
RK-33 is an RNA helicase inhibitor against DDX3, and inhibits its helicase activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.63%
- CAS No.: 1070773-09-9
- Formule: C23H20N6O3
- Masse moléculaire:428.44
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
-
Anti-Aging Compound Library
HY-L034
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) RK-33
More
Customer Validation & Images
-
Flow Cytometry
-
Flow Cytometry
-
WB
-
ELISA
-
Flow Cytometry
Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
|
Helicase |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
2.5 μM
Compound: 1
|
Cytotoxicity against human A549 cells after 72 hrs by WST1 assay
Cytotoxicity against human A549 cells after 72 hrs by WST1 assay
|
[PMID: 21572541] |
| A549 | IC50 |
2.56 μM
Compound: 1
|
Cytotoxicity against human A549 cells after 72 hrs by WST1 assay
Cytotoxicity against human A549 cells after 72 hrs by WST1 assay
|
[PMID: 23290252] |
| Daoy | IC50 |
2.5 μM
Compound: RK-33
|
Antiproliferative activity against human Daoy cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay
Antiproliferative activity against human Daoy cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay
|
[PMID: 33636537] |
| Huh-7 | CC50 |
<10 μM
Compound: 51
|
Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability
Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability
|
[PMID: 35899912] |
| MCF7 | IC50 |
7.5 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 72 hrs by WST1 assay
Cytotoxicity against human MCF7 cells after 72 hrs by WST1 assay
|
[PMID: 21572541] |
| MCF7 | IC50 |
7.59 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 72 hrs by WST1 assay
Cytotoxicity against human MCF7 cells after 72 hrs by WST1 assay
|
[PMID: 23290252] |
| MDA-MB-231 | IC50 |
4.01 μM
Compound: 1
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by WST1 assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by WST1 assay
|
[PMID: 21572541] |
| MDA-MB-231 | IC50 |
4.05 μM
Compound: 1
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by WST1 assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by WST1 assay
|
[PMID: 23290252] |
| NCI-H460 | IC50 |
2.8 μM
Compound: 1
|
Cytotoxicity against human H460 cells after 72 hrs by WST1 assay
Cytotoxicity against human H460 cells after 72 hrs by WST1 assay
|
[PMID: 21572541] |
| NCI-H460 | IC50 |
2.87 μM
Compound: 1
|
Cytotoxicity against human H460 cells after 72 hrs by WST1 assay
Cytotoxicity against human H460 cells after 72 hrs by WST1 assay
|
[PMID: 23290252] |
| OVCAR-3 | IC50 |
14.5 μM
Compound: 1
|
Cytotoxicity against human OVCAR3 cells after 72 hrs by WST1 assay
Cytotoxicity against human OVCAR3 cells after 72 hrs by WST1 assay
|
[PMID: 21572541] |
| OVCAR-3 | IC50 |
14.5 μM
Compound: 1
|
Cytotoxicity against human OVCAR3 cells after 72 hrs by WST1 assay
Cytotoxicity against human OVCAR3 cells after 72 hrs by WST1 assay
|
[PMID: 23290252] |
| PC-3 | IC50 |
4.8 μM
Compound: 1
|
Cytotoxicity against human PC3 cells after 72 hrs by WST1 assay
Cytotoxicity against human PC3 cells after 72 hrs by WST1 assay
|
[PMID: 21572541] |
| PC-3 | IC50 |
4.9 μM
Compound: 1
|
Cytotoxicity against human PC3 cells after 72 hrs by WST1 assay
Cytotoxicity against human PC3 cells after 72 hrs by WST1 assay
|
[PMID: 23290252] |
| Vero | CC50 |
29.7 μM
Compound: 51
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 22 hrs by XTT assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 22 hrs by XTT assay
|
[PMID: 35899912] |
| Vero C1008 | CC50 |
>30 μM
Compound: 51
|
Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability
Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability
|
[PMID: 35899912] |
RK-33 shows inhibition of many kinds of cancer cells with IC50 of 3-6 μM, while PC3 is much less sensitive to RK-33 (IC50 >12 μM). RK-33 treatment causes a significant accumulation in the G1 phase for DU145 and LNCaP, although treatment with RK-33 causes only a moderate accumulation of the G1 phase for 22Rv1, and the treated cells have significantly reduced G2 phase. RK-33 treatment also causes 12 moderate G1 accumulation in 22Rv1[1]. RK-33-loaded NPs demonstrate cytotoxicity to MCF-7 cells in a dose-dependent manner, while equivalent doses of empty NPs have no killing effect. The IC50 value of 5% RK-33 loaded NPs is 49 μg/mL, and the IC50 value of 10% RK-33 loaded NPs is 25 μg/mL[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1070773-09-9
-
Appearance Solid
-
Masse moléculaire 428.44
-
Formule C23H20N6O3
-
Color Light yellow to yellow
-
SMILES
O=C1N(CC2=CC=C(OC)C=C2)C3=NC=NC4=C(N=CN4CC5=CC=C(OC)C=C5)C3=N1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Free Radic Biol Med
YAP-mediated DDX3X confers resistance to ferroptosis in breast cancer cells by reducing lipid peroxidation. [Abstract]2025 May:232:330-339. PMID: 40089076
RK-33 purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 May:232:330-339. [Abstract]
RK-33 (5 μM; 24 h), a DDX3-specific inhibitor, reinforced increased lipid peroxidation levels in BT549 cells in the presence of hydrogen peroxide.
RK-33 purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 May:232:330-339. [Abstract]
RK-33 (5 μM; 24 h) elevated the levels of lipid peroxidation in MCF7/DDX3X-HA cells when they were exposed to hydrogen peroxide.
RK-33 purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 May:232:330-339. [Abstract]
RK-33 (5-10 μM; 24 h) dose-dependently suppressed GPX4 protein levels in BT549 and MCF7 cells.
-
Int Immunopharmacol
Inhibition of DDX3X alleviates persistent inflammation, immune suppression and catabolism syndrome in a septic mice model. [Abstract]2023 Apr:117:109779. PMID: 36806038
RK-33 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2023 Apr:117:109779. [Abstract]
RK-33 (20 mg/kg; i.p.; once daily) down-regulated the levels of CRP, IL-6 and TNF-α in the peripheral blood of CLP-induced septic mice.
RK-33 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2023 Apr:117:109779. [Abstract]
RK-33 (20 mg/kg; i.p.; once daily) improved the total number of CD4+ and CD8+ T cells in septic mice reduced by CLP.
-
NonCoding RNA
DEAD-Box Helicase 3 Modulates the Non-Coding RNA Pool in Ribonucleoprotein Condensates During Stress Granule Formation. [Abstract]2025 Aug 1;11(4):59. PMID: 40863725 -
Brain Res
DDX3X promotes ILF3 stability to accelerate neuroblastoma progression via M2 macrophage polarization. [Abstract]2026 Jan 15:1871:150071. PMID: 41314490 -
Solvant et solubilité
DMSO : 25 mg/mL (58.35 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 2 mg/mL (4.67 mM); Suspended solution; Need ultrasonic
Protocole
Briefly, 8×102 MCF-7 cells are seeded in a 96-well plate, and treated with different concentrations of RK-33 loaded nanoparticles and unloaded nanoparticles next day. After 72-h incubation, MTS reagent is added to the cells, and the absorbance is measured at 490 nm after 2-h incubation with MTS reagent. The experiment is repeated three independent times.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice are randomLy redistributed into four groups of eight according to their tumor growth, which results in an approximately equal distribution of tumor size at the beginning of radiation and RK-33 drug treatment. The four groups of mice are blindly chosen for four different experimental procedures, including control (injection of DMSO only), RK-33 treatment (injection of RK-33 only 50 mg/kg), radiation (one-time radiation of 5 Gy), or radiation and RK-33 treatment (combination of radiation of 5 Gy and RK-33 injection). RK-33 and DMSO are injected intraperitoneally thrice weekly for two weeks. Radiation is performed at the beginning of drug injection using the Small Animal Radiation Research Platform (SARRP) with a circular beam of 1 cm diameter, focusing on the tumor site. Mice of each group are euthanized 0 h and 24 h after radiation and tumors are extracted for γH2AX, cleaved Caspase 3, and Ki67 staining. The remaining mice of each group are imaged with a Xenogen IVIS Spectrum, with injection of D-luciferin 5 minutes before imaging. Mice are euthanized after six weeks of imaging and tumors are extracted for H&E staining, cleaved Caspase 3, and i67 staining. Morphology of the tumors after RK-33 and radiation treatment is assessed by a veterinary pathologist on hematoxylin and eosin stained sections.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Xie M,et al. RK-33 radiosensitizes prostate cancer cells by blocking the RNA helicase DDX3. Cancer Res. 2016 Sep 12. [Content Brief]
[2]. Bol GM, e tal. PLGA nanoparticle formulation of RK-33: an RNA helicase inhibitor against DDX3. Cancer Chemother Pharmacol. 2015 Oct;76(4):821-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3340 mL | 11.6702 mL | 23.3405 mL | 58.3512 mL |
| 5 mM | 0.4668 mL | 2.3340 mL | 4.6681 mL | 11.6702 mL | |
| 10 mM | 0.2334 mL | 1.1670 mL | 2.3340 mL | 5.8351 mL | |
| 15 mM | 0.1556 mL | 0.7780 mL | 1.5560 mL | 3.8901 mL | |
| 20 mM | 0.1167 mL | 0.5835 mL | 1.1670 mL | 2.9176 mL | |
| 25 mM | 0.0934 mL | 0.4668 mL | 0.9336 mL | 2.3340 mL | |
| 30 mM | 0.0778 mL | 0.3890 mL | 0.7780 mL | 1.9450 mL | |
| 40 mM | 0.0584 mL | 0.2918 mL | 0.5835 mL | 1.4588 mL | |
| 50 mM | 0.0467 mL | 0.2334 mL | 0.4668 mL | 1.1670 mL |
RK-33 Related Classifications
HY-100455 Related Classifications
Powered by Bioz